Mes: septiembre 2019

Several drugs are scoring big wins against common cancers, setting new standards for how to treat many prostate, breast and lung tumors. There’s even a “uni-drug” that may fight many forms of the disease. What’s especially striking: The drugs are beneficial in some cases for more than a year, much longer than the few months many new drugs provide.  Here are some highlights from the world’s largest cancer meeting, the American Society of Clinical Oncology conference in Chicago: Janssen Biotech’s Zytiga improved survival and delayed cancer growth for 18 months when added to standard care in a study of 1,200 men with advanced prostate cancer. The drug is approved to treat tumors that are resistant to hormone therapy; this study tested it as an initial treatment. More in Cancer The study was stopped early because men on Zytiga were living longer — 66 percent were alive after three years versus 49 percent of a comparison group not given the drug. Zytiga also delayed the time until cancer worsened — 33 months versus 15 months for the others. In a second study of 1,900 men newly diagnosed with advanced prostate cancer, adding Zytiga to usual treatment also improved survival: 83 percent were alive at three years versus 76 percent of men not given the drug. Zytiga also cut the chance of relapse and serious bone problems. Zytiga caused more side...

Several drugs are scoring big wins against common cancers, setting new standards for how to treat many prostate, breast and lung tumors. There’s even a “uni-drug” that may fight many forms of the disease. What’s especially striking: The drugs are beneficial in some cases for more than a year, much longer than the few months many new drugs provide.  Here are some highlights from the world’s largest cancer meeting, the American Society of Clinical Oncology conference in Chicago: Janssen Biotech’s Zytiga improved survival and delayed cancer growth for 18 months when added to standard care in a study of 1,200 men with advanced prostate cancer. The drug is approved to treat tumors that are resistant to hormone therapy; this study tested it as an initial treatment. More in Cancer The study was stopped early because men on Zytiga were living longer — 66 percent were alive after three years versus 49 percent of a comparison group not given the drug. Zytiga also delayed the time until cancer worsened — 33 months versus 15 months for the others. In a second study of 1,900 men newly diagnosed with advanced prostate cancer, 포커사이트 adding Zytiga to usual treatment also improved survival: 83 percent were alive at three years versus 76 percent of men not given the drug. Zytiga also cut the chance of relapse and serious bone problems. Zytiga caused more...